Page 44 - 82_01
P. 44
Coronary ischemia-reperfusion: role of nitric oxide and endothelin-1. A Review
W, H RamuzH. Pathophysiological role of endothelin 88. Diéguez G, García JL, Fernández N, García-Villalón
revealed by the first orally active endothelin receptor AL, Monge L, Gómez B. Cerebrovascular and
antagonist. Nature 1993;365:759–61. coronary effects of endothelin-1 in the goat. Am J
Physiol 1992; 263 (4):R834-9.
75. Brunner F, Bras-Silva C, Cerdeira AS, Leite-Moreira
AF. Cardiovascular endothelins: essential regulators 89. García-Villalón AL, Amezquita YM, Monge L,
of cardiovascular homeostasis. Pharmacol Ther Fernández N, Salcedo A, Diéguez G. Endothelin-1
2006;111:508–31. potentiation of coronary artery contraction after
ischemia-reperfusion. Vascul Pharmacol 2008; 48 (2-
76. Russell FD, Davenport AP. Secretory pathways in 3):109-14, .
endothelin synthesis. Br J Pharmacol 1999;126:391–
98. 90. Climent B, Fernández N, Sanz E, Sánchez A, Monge
L, García-Villalón A-L, Diéguez G. Enhanced
77. Callera G, Tostes R, Savoia C, Muscara MN, Touyz response of pig coronary arteries to endothelin-1 after
RM. Vasoactive peptides in cardiovascular (patho) ischemia-reperfusion. Role of endothelin receptors,
physiology. Expert Rev Cardiovasc Ther 2007;5:531– nitric oxide and prostanoids. Eur J Pharmacol 2005;
52. 524, 102-10.
78. Kedzierski RM, Yanagisawa M. Endothelin system: 91. Bax WA, Bruinvels AT, van Suylen R-J, Saxena PR,
the double-edged sword in health and disease. Annu Hoyer D. Endothelin receptors in the human coronary
Rev Pharmacol Toxicol2001; 41:851–76. artery, ventricle and atrium. A quantitative
autoradiographic analysis, Naunyn-Schmiedeberg's
79. Anggrahini DW, Emoto N, Nakayama K, Widyantoro Arch Pharmacol 1993; 348:403-10.
B, Adiarto S, Iwasa N, Nonaka H, Rikitake Y,
Kisanuki YY, Yanagisawa M, Hirata K. Vascular 92. Ushio-Fukai M, Nishimura J, Kobayashi S, Kanaide H.
endothelial cell-derived endothelin-1 mediates Endothelin-1 and endothelin-3 regulate differently
vascular inflammation and neointima formation vasoconstrictor responses of smooth muscle of the
following blood flow cessation. Cardiovasc Res 2009; porcine coronary artery. Br J Pharmacol 1995; 114
82:143–51. (1):171-79.
80. Nguyen A, Thorin-Trescases N, Thorin E. Working 93. Wang Q-D, Li X-S, Pernow J. Characterization of
under pressure: coronary arteries and the endothelin endothelin-1-induced vascular effects in the rat heart
system. Am J Physiol Regul Integr Comp Physiol by using endothelin receptor antagonists Eur. J.
2010; 298 (5):R1188-94. Pharmacol1995; 271 (1):25-30.
81. Halcox JP, Nour KR, Zalos G, Quyyumi AA. Coronary 94. Balwierczak JL. Two subtypes of the endothelin
vasodilation and improvement in endothelial receptor (ETA and ETB) mediate vasoconstriction in
dysfunction with endothelin ET (A) receptor the perfused rat heart. J Cardiov Pharmacol 1993; 22
blockade. Circ Res 2001; 89:969–76. (Suppl. 8): S248.
82. Callera G, Tostes R, Savoia C, Muscara MN, Touyz 95. Riegel DF, Ñappe RW. Differential responsiveness of
RM. Vasoactive peptides in cardiovascular (patho) conduit and resistance coronary arteries to endothelin
physiology. Expert Rev Cardiovasc Ther 2007; 5:531– A and B receptor stimulation in anesthtized dogs. J.
52. Cardiov. Pharmacol 1003; 22 (Suppl. 8): S243.
83. Thorin E, Parent R, Ming Z, Lavallee M. Contribution 96. García JL, Fernández N, García-Villalón AL, Monge
of endogenous endothelin to large epicardial coronary L, Gómez B, Diéguez G.. Coronary vasoconstriction
artery tone in dogs and humans. Am J Physiol Heart by endothelin-1 in anesthetized goats: role of
Circ Physiol 1999;277:H524–H532. endothelin receptors, nitric oxide and prostanoids. Eur
J Pharmacol 1996; 315 (2):179-86.
84. Ezra, D, Goldstein RE, Czaja JF, Feuerstein GZ.
Lethal ischemia due to intracoronary endothelin in 97. García-Villalón AL, Fernández N, Monge L, Salcedo
pigs. Am. J. Physiol. 257 (Heart Circ. Physiol 1989; A, Diéguez G. Effects of endothelin-1 on the
257 (1): H339-H343. relaxation of rat coronary arteries. J Cardiovasc
Pharmacol 2009; 54 (5):445-50.
85. Kurihara H, Yamaoki K, Nagai R, Yoshizumi M,
Takaku F, Satoh H, Inui J, Yazaki Y. Endothelin: a 98. Fernández N, García JL, García-Villalón AL, Monge
potent vasoconstrictor associated with coronary L, Gómez B, Diéguez G. Coronary vasoconstriction
vasospasm. Life Sci1989; 44: 1937-43. produced by vasopressin in anesthetized goats. Role of
vasopressin V1 and V2 receptors and nitric oxide. Eur
86. Chester AH, Dashwood MR, Clarke JG, Larkin SW, J Pharmacol 1998; 26;342 (2-3):225-33.
Davies GJ, Tadjkarimi S, Maseri A, Yacoub MH.
Influence of endothelin on human coronary arteries 99. García-Villalón AL, Garcia JL, Fernández N, Monge
and localization of its binding sites. Am. J. Cardiol L, Gómez B, Diéguez G Regional differences in the
1989; 63: 1395-98. arterial response to vasopressin: role of endothelial
nitric oxide. Br J Pharmacol 1996; 118 (7):1848-54.
87. Franco-Cereceda A. Endothelin- and neuropeptide Y-
induced vasoconstriction of human epicardial 100. Martínez MA, Fernández N, García-Villalón AL,
coronary arteries in vitro. Br. J. Pharmacol1989; Monge L, Diéguez G. Comparison of the in vivo
97:968-72.
@Real Academia Nacional de Farmacia. Spain 43
